Cell biology - Lessons in rational drug design for protein kinases

被引：14

作者：

Ahn, NG ^{[1
]}

Resing, KA ^{[1
]}

机构：

[1] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA

来源：

SCIENCE | 2005年 / 308卷 / 5726期

关键词：

D O I：

10.1126/science.1113707

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

[No abstract available]

引用

页码：1266 / 1267

页数：2

共 8 条

[1]

Bridges AJ, 1999, CURR MED CHEM, V6, P825

[2] Structural bioinformatics-based design of selective, irreversible kinase inhibitors [J].

Cohen, MS ;

Zhang, C ;

Shokat, KM ;

Taunton, J .

SCIENCE, 2005, 308 (5726) :1318-1321

[3] The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].

Deininger, M ;

Buchdunger, E ;

Druker, BJ .

BLOOD, 2005, 105 (07) :2640-2653

[4] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[5] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[6] Structural basis for selective inhibition of Src family kinases by PP1 [J].

Liu, Y ;

Bishop, A ;

Witucki, L ;

Kraybill, B ;

Shimizu, E ;

Tsien, J ;

Ubersax, J ;

Blethrow, J ;

Morgan, DO ;

Shokat, KM .

CHEMISTRY & BIOLOGY, 1999, 6 (09) :671-678

[7] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].

Pao, W ;

Miller, VA ;

Politi, KA ;

Riely, GJ ;

Somwar, R ;

Zakowski, MF ;

Kris, MG ;

Varmus, H .

PLOS MEDICINE, 2005, 2 (03) :225-235

[8] Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions [J].

Pao, W ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2556-2568

← 1 →